Where does Trevi Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$42.76M+10.8%	-$47.91M-64.8%	-$29.07M+0.3%	-$29.15M+14.1%
Depreciation and amortization	$144K-2.0%	$147K+19.5%	$123K+186%	$43K-14.0%
Stock-based compensation	$5.19M+44.5%	$3.59M+65.2%	$2.17M-6.7%	$2.33M-8.5%
Change in accounts payable	——	$1.61M—	——	$9K—
Change in accrued liabilities	——	——	$52K+108%	-$639K-290%
Change in other assets	——	-$2.74M-193%	$2.94M—	——
Non-cash operating lease expense	$437K-5.0%	$460K—	——	——
Net cash from operating activities	-$42.09M-10.0%	-$38.26M-20.6%	-$31.71M-12.5%	-$28.18M+2.7%
Capital expenditures	——	——	$137K—	——
Proceeds from maturities/sales of investments	$76.57M-0.5%	$76.97M+10.8%	$69.5M—	——
Net cash from investing activities	-$94.11M—	——	$59.43M—	——
Proceeds from issuance of common stock	$2.08M+428%	$394K+432%	$74K-66.4%	$220.25K—
Payments for finance leases	$11K-91.3%	$127K+32.3%	$96K—	——
Net cash from financing activities	$121.01M+96.8%	$61.48M—	——	$111.31M+436%
Net increase (decrease) in cash	-$15.18M-993%	$1.7M-91.4%	$19.81M+182%	-$24.24M—
Accretion (Amortization) of Discounts and Premiums, Investments	$1.64M+19.8%	$1.37M-35.7%	$2.13M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	-$2.74M-193%	$2.94M—	——
Operating lease right-of-use asset amortization	$437K-5.0%	$460K—	——	——
Write Off Of Deferred Offering Costs	$26K—	——	$390K—	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$76.57M-0.5%	$76.97M+10.8%	$69.5M—	——
Finance Lease, Principal Payments	$11K-91.3%	$127K+32.3%	$96K—	——
Payments Of Stock Issuance Costs	$809K—	——	$258K+9.3%	$236K-43.8%
Proceeds From Offering Net Of Commissions	$108.15M+130%	$47M—	——	——
Proceeds From Warrant Exercises	——	——	——	$11.78M+392,633%
Offering Costs Included In Accrued Expenses	——	$233K—	——	$15K-63.4%
Free cash flow	——	——	-$31.85M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Trevi Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.